Casdin Capital

Type

Venture Capital

Status

Active

Location

New York, United States

Total investments

205

Average round size

98M

Portfolio companies

149

Rounds per year

17.08

Lead investments

16

Follow on index

0.27

Exits

41

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyArtificial IntelligenceHealth CareHealth DiagnosticsGeneticsMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Casdin Capital appeared to be the VC, which was created in 2011. The leading representative office of defined VC is situated in the New York. The company was established in North America in United States.

The fund is constantly included in 2-6 investment rounds annually. This Casdin Capital works on 13 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. The typical startup value when the investment from Casdin Capital is more than 1 billion dollars.

The usual cause for the fund is to invest in rounds with 7-8 partakers. Despite the Casdin Capital, startups are often financed by The Column Group, ARCH Venture Partners, Topspin Partners. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Redmile Group, Wellington Management. In the next rounds fund is usually obtained by Redmile Group, Perceptive Advisors, GV.

We also calculated 2 valuable employees in our database.

The fund has no exact preference in some founders of portfolio startups. When startup sums 1 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Flatiron Health, 23andMe. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Show more

Investor highlights

Industry focus
HealthcareBiotech/Life Sciences
Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
205
Lead investments
16
Exits
41
Rounds per year
17.08
Follow on index
0.27
Investments by industry
  • Biotechnology (163)
  • Health Care (108)
  • Therapeutics (58)
  • Medical (49)
  • Life Science (42)
  • Show 50 more
Investments by region
  • United States (176)
  • United Kingdom (7)
  • France (7)
  • Switzerland (3)
  • Netherlands (2)
  • Show 5 more
Peak activity year
2021
Number of Unicorns
9
Number of Decacorns
10
Number of Minotaurs
5

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
269M
Group Appearance index
0.94
Avg. company exit year
9
Avg. multiplicator
6.10
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Basilard BioTech 06 Oct 2021 Biotechnology, Life Science, Biopharma Seed United States, California, California
Idrx 02 Aug 2022 Biotechnology, Life Science, Product Research Early Stage Venture 122M

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.